Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review

Adam M Henrie
James J Nawarskas
Joe R Anderson
College of Pharmacy, University of New Mexico, Albuquerque, NM, USA

Abstract: Pulmonary arterial hypertension (PAH) is a chronic and disabling condition characterized by an elevated pulmonary vascular resistance and an elevated mean pulmonary arterial pressure. Despite recent improvements in treatment availability, PAH remains challenging to treat, burdensome for patients, and ultimately incurable. Tadalafil is a phosphodiesterase-5 inhibitor that is administered once daily by mouth for the treatment of PAH. Current treatment guidelines recommend tadalafil as an option for patients with World Health Organization functional class II or III PAH. In a placebo-controlled clinical trial, patients taking tadalafil demonstrated significantly improved exercise capacity as measured by the 6-minute walk distance. Patients also experienced decreased incidence of clinical worsening, increased quality of life, and improved cardiopulmonary hemodynamics. Uncontrolled studies and smaller trials have indicated a possible role for tadalafil as a suitable alternative to sildenafil and as a beneficial add-on option when used in combination with other treatments for PAH. Tadalafil is generally safe and well tolerated. Adverse events are typically mild-to-moderate in intensity, and discontinuation rates are usually low. The purpose of this review is to provide an evidence-based evaluation of the clinical utility of tadalafil in the treatment of PAH.

Keywords: tadalafil, phosphodiesterase-5 inhibitor, pulmonary arterial hypertension

Core evidence clinical impact summary

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Evidence</th>
<th>Implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease-oriented evidence</td>
<td>Clinical trials</td>
<td>Tadalafil has consistently demonstrated efficacy in improving exercise capacity when used as monotherapy. Tadalafil may also increase time to clinical worsening and improve cardiopulmonary hemodynamics when used as monotherapy. Strong evidence from large controlled trials supporting additional benefit of using tadalafil in combination therapy is lacking.</td>
</tr>
<tr>
<td>Patient-oriented evidence</td>
<td>Clinical trials</td>
<td>Tadalafil has demonstrated efficacy in improving patient quality of life when used as monotherapy. Tadalafil is generally safe and well tolerated.</td>
</tr>
<tr>
<td>Economic evidence</td>
<td>None available</td>
<td>None available</td>
</tr>
</tbody>
</table>

Correspondence: Joe R Anderson
College of Pharmacy, University of New Mexico, MSC09 3360, Albuquerque, NM 87131-0001, USA
Tel +1 505 272 3664
Email janderson@salud.unm.edu
Introduction

Pulmonary arterial hypertension (PAH) is a rare, however, debilitating chronic condition that remains progressive and incurable despite recent approval of several novel treatment options. In PAH, blood flow through the lungs is impaired, resulting in increased pulmonary vascular resistance (PVR) and an elevated mean pulmonary arterial pressure (mPAP). These factors often lead to pulmonary vasculature fibrosis and eventual right ventricular heart failure.  

Pulmonary hypertension is classified by the World Health Organization (WHO) into five groups based on a diversity of etiologies, including group 1: PAH, which is idiopathic, heritable, drug/toxin induced, or associated with connective tissue disease, portal hypertension, HIV infection, or congenital heart disease; group 2: pulmonary hypertension due to left heart disease; group 3: pulmonary hypertension due to lung disease; group 4: chronic thromboembolic pulmonary hypertension; and group 5: pulmonary hypertension with unclear multifactorial mechanisms. 

Patients with PAH commonly present with dyspnea on exertion; however, additional symptoms, including fatigue, weakness, angina, syncope, palpitations, and lower extremity edema, may also be present. The severity of PAH is based upon patient symptoms and activity level and is categorized by the WHO functional classification scheme which is as follows: WHO Class I patients have no limitation in physical activity and do not experience symptoms (dyspnea, fatigue, chest pain, or near syncope) with ordinary physical activity; WHO Class II patients have a slight limitation in physical activity experiencing symptoms with ordinary physical activity; WHO Class III patients have a marked limitation in physical activity experiencing symptoms with less than ordinary activity; and WHO Class IV patients are unable to carry out any physical activity without symptoms and experience symptoms at rest or with very slight activity. The 6-minute walk distance (6MWD) and the Borg dyspnea scale are often employed by clinicians and researchers to quantify a patient’s exercise capacity and breathing difficulty as well as to gage response to treatment. Cardiopulmonary hemodynamics, including PVR, mPAP, pulmonary arterial wedge pressure, and cardiac index (CI), are also obtained and assessed throughout the disease diagnostic and monitoring process.

PAH is associated with poor survival, increased morbidity, and diminished quality of life (QoL). Patients often require a multidisciplinary approach to treatment in which needs relating to physical care as well as emotional and social care can be met. Currently, a number of guidelines exist to aid clinicians in treating patients with PAH. Although the available guidelines vary slightly in content, they generally agree in treatment approach. Goals of the treatment include improvement of symptoms, QoL, and survival. Patients who have less severe disease and who respond during acute vasoreactivity testing are initially started on a trial therapy with an oral calcium channel blocker (CCB). Patients who either fail to respond during acute vasoreactivity testing, fail to maintain a response while taking an oral CCB, or present with more severe diseases are considered for treatment with other approved options. Prostaglandin analogs (epoprostenol, iloprost, treprostinil), endothelin receptor antagonists (ERAs; ambrisentan, bosentan, macitentan), phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, tadalafil), and a soluble guanylate cyclase (sGC) stimulator (riociguat) are all currently available for the treatment of PAH (Table 1). Oral agents, such as ERAs, PDE-5 inhibitors, treprostinil, and riociguat, are recommended for patients with WHO functional class II. Patients with WHO functional class III are treated with either an oral medication or a prostacyclin analog (inhaled or parenteral). Patients at higher risk, WHO functional class IV, should be treated with intravenous epoprostenol. Variations from this approach as well as treatment after inadequate clinical response to initial therapy can include strategies such as combination therapy and are preferentially implemented at expert PAH care centers according to the clinician’s judgment. Adjunctive therapies, including diuretics, anticoagulants, digoxin, or supplemental oxygen, may also be employed to better achieve treatment goals.

Although the causal mechanisms for the pathogenesis of PAH remain unclear, the progression of PAH is the result of pulmonary arterial endothelial dysfunction leading to an imbalance between key pulmonary vascular mediators, such as decreased nitric oxide (NO) and prostacyclin and increased endothelin-1. This imbalance leads to increased thrombosis, vasoconstriction, and proliferation of smooth muscle and endothelial cells within the pulmonary vasculature. Current treatments are directed at correcting the imbalance in these mediators.

While the body of evidence supporting PAH treatment is continually growing, there remain several important limitations to current treatment recommendations. PAH has many etiologies, including some which remain grouped as idiopathic. Studies have used a broad definition of PAH in patient recruitment resulting in efficacy data from a heterogeneous selection of etiologies. As such, there are limitations in knowledge about specific treatment efficacy in each form of PAH. Furthermore, a few studies have evaluated the
Table 1 Treatment options for pulmonary arterial hypertension

<table>
<thead>
<tr>
<th>Treatment option</th>
<th>Route of administration</th>
<th>Dosing frequency (doses/day)</th>
<th>Restricted dispensing</th>
<th>Relative cost*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium channel blockers</td>
<td>Oral</td>
<td>Various</td>
<td>No</td>
<td>$</td>
</tr>
<tr>
<td>Prostacyclin analogs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epoprostenol</td>
<td>Intravenous</td>
<td>Continuous</td>
<td>No</td>
<td>$$</td>
</tr>
<tr>
<td>Iloprost</td>
<td>Inhaled</td>
<td>6–9</td>
<td>No</td>
<td>$$$</td>
</tr>
<tr>
<td>Treprostinil</td>
<td>Intravenous/subcutaneous</td>
<td>Continuous</td>
<td>No</td>
<td>$$$</td>
</tr>
<tr>
<td></td>
<td>Inhaled</td>
<td>4</td>
<td>No</td>
<td>$$</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>2–3</td>
<td>No</td>
<td>$$</td>
</tr>
<tr>
<td>Endothelin receptor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antagonists</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ambrisentan</td>
<td>Oral</td>
<td>1</td>
<td>Yes</td>
<td>$$$</td>
</tr>
<tr>
<td>Bosentan</td>
<td>Oral</td>
<td>2</td>
<td>Yes</td>
<td>$$$</td>
</tr>
<tr>
<td>Macitentan</td>
<td>Oral</td>
<td>1</td>
<td>Yes</td>
<td>$$$</td>
</tr>
<tr>
<td>Phosphodiesterase-5 inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sildenafil</td>
<td>Oral</td>
<td>3</td>
<td>No</td>
<td>$$</td>
</tr>
<tr>
<td>Tadalafil</td>
<td>Oral</td>
<td>1</td>
<td>No</td>
<td>$$</td>
</tr>
<tr>
<td>Soluble guanylate cyclase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stimulator</td>
<td>Oral</td>
<td>3</td>
<td>Yes</td>
<td>$$$</td>
</tr>
</tbody>
</table>

Notes: *According to average wholesale price in 2015 US dollars for a 75 kg patient. $, cost/year < $20,000; $$, cost/year = $20,000–$50,000; $$$, cost/year >$50,000.

relative utility of available treatment options in head-to-head comparisons. This has resulted in a paucity of data supporting the use of a specific agent as first-line treatment.\textsuperscript{5,14} In addition to limitations in treatment recommendations, currently available treatment options can be at times challenging and burdensome to use. With the exception of CCBs, there are no means to effectively predict benefit from the available treatment options.\textsuperscript{4} Treatment options can be overly burdensome to patients as a result of high cost, frequent dosing, and inconvenient administration. Several agents are contraindicated in pregnancy and possess clinically important drug interactions.\textsuperscript{4,9} These limitations and others drive in part the need for novel treatment options. The purpose of this review is to provide an evidence-based evaluation of the clinical utility of tadalafil in the treatment of PAH.

**Tadalafil**

As mentioned previously, NO production and release is decreased as a result of endothelial dysfunction.\textsuperscript{13} NO causes vasodilation of the pulmonary vasculature by increasing the production of the second messenger cyclic guanosine monophosphate (cGMP) via activation of sGC (Figure 1).\textsuperscript{16} cGMP activates protein kinase G, which in turn activates sarcolemmal potassium channels. This results in intracellular hyperpolarization and inhibition of voltage-gated calcium channels ultimately leading to vasorelaxation.\textsuperscript{17} Thus, the decrease in NO availability seen in PAH results in decreased cGMP and increased pulmonary arterial vasoconstriction. PDE-5 is the predominant phosphodiesterase in the pulmonary vasculature and is responsible for the rapid degradation and inactivation of cGMP.\textsuperscript{18,19} Treatment with PDE-5 inhibitors (sildenafil or tadalafil) results in a competitive inhibition of cGMP degradation resulting in increased cGMP concentrations.\textsuperscript{20} The increased cGMP concentrations lead to relaxation of pulmonary vascular smooth muscle and vasodilation of the pulmonary vascular bed.\textsuperscript{16} Currently, sildenafil (Revatio®) and tadalafil (Adcirca®) are the only PDE-5 inhibitors approved by the United States Food and Drug Administration for the treatment of WHO group 1 PAH.\textsuperscript{21,22} Other PDE-5 inhibitors, such as vardenafil, have not been approved for the treatment of PAH, and the limited evidence available using these drugs in the treatment of PAH prohibit meaningful comparison to tadalafil. Several pharmacokinetic and pharmacodynamic differences exist between sildenafil and tadalafil (Table 2). One of the main pharmacokinetic differences is the long plasma half-life (t\textsubscript{1/2}) of 17.5 hours with tadalafil, which facilitates once-daily dosing as compared to the required three times daily dosing of sildenafil.\textsuperscript{22,23} When compared to sildenafil, the less frequent dosing of tadalafil is advantageous in terms of patient convenience and adherence.\textsuperscript{24} Tadalafil is primarily metabolized by the cytochrome P450 3A (CYP3A) enzyme subfamily to an inactive metabolite. As such, concomitant administration with medications that induce or inhibit CYP3A may result in significant drug–drug interactions.\textsuperscript{21,25} Bosentan, an ERA used in the treatment of PAH, induces
CYP3A4 and has been demonstrated to decrease tadalafil serum concentrations and exposure. Although tadalafil is not primarily eliminated renally, starting doses of tadalafil require adjustment in patients with a creatinine clearance (CrCl) of 31–80 mL/min, and tadalafil should be avoided in patients with a CrCl <30 mL/min or in patients on hemodialysis.

The pharmacodynamic differences between sildenafil and tadalafil are based on each agent’s selectivity for various PDE isozymes. Tadalafil is 1,000-fold more selective for PDE-5 than for PDE-1–4 and PDE-7–10, 780-fold more selective for PDE-5 than for PDE-6, and only seven-fold more selective for PDE-5 than for PDE-11. In comparison, sildenafil is 41-fold more selective for PDE-5 than for PDE-1, seven-fold more selective for PDE-5 than for PDE-6, and 203-fold more selective for PDE-5 than for PDE-11. These differences in selectivity may result in the differences in adverse effects dependent on the isozyme location and activity. PDE-6 is expressed only in the retina and is important for visual transduction. Inhibition of PDE-6 can result in visual disturbances, which have been more frequently reported with sildenafil than with tadalafil. PDE-1 is expressed in the brain, myocardial cells, and vascular smooth muscle cells. Inhibition of PDE-1 may cause vasodilatation, flushing, and tachycardia. PDE-11 is expressed in the liver, kidney, skeletal muscle, prostate, and testes. Tadalafil is less selective for PDE-11 than sildenafil and is more likely to be associated with back pain and myalgias than with sildenafil.

Tadalafil, as well as other PDE-5 inhibitors, has several pharmacodynamic drug–drug interactions of concern. Tadalafil does not significantly lower systemic blood pressure; however, concomitant administration of tadalafil with medications that do lower systemic blood pressure can result in potentiation of hypotension. Coadministration of tadalafil with nitrates is contraindicated due to the risk

Figure 1 The role of phosphodiesterase-5 (PDE-5) in the intracellular signaling pathway of the pulmonary vasculature.

Notes: NO and NPs bind to soluble and particulate guanylate cyclase, respectively, causing enzymatic activation and conversion of GTP to cGMP. Through the activation of protein kinase G, cGMP serves as a second messenger leading to cellular response resulting in pulmonary artery vasodilation. cGMP degradation to GMP by PDE-5 limits this cellular response. Thus, inhibition of PDE-5 by tadalafil results in an enhanced cellular response to vasodilative ligands. Data from Moncada and Higgs, and Archer et al.

Abbreviations: NO, nitric oxide; NPs, natriuretic peptides; GTP, guanosine triphosphate; cGMP, cyclic guanosine monophosphate; GMP, guanosine monophosphate; PDE-5, phosphodiesterase-5.

Table 2 Phosphodiesterase-5 inhibitors used for the treatment of pulmonary hypertension

<table>
<thead>
<tr>
<th>Agent</th>
<th>$T_{\text{max}}$</th>
<th>Hepatic metabolism</th>
<th>Half-life</th>
<th>Dose</th>
<th>Renal dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sildenafil (Revatio)$^{22}$</td>
<td>60 minutes</td>
<td>CYP3A (major), CYP2C9 (minor)</td>
<td>4 hours</td>
<td>20 mg 3 times a day approximately 4–6 hours apart</td>
<td>None required</td>
</tr>
<tr>
<td>Tadalafil (Adcirca)$^{21}$</td>
<td>75–90 minutes</td>
<td>CYP3A</td>
<td>17.5 hours</td>
<td>40 mg (2×20 mg) once daily; CrCl 31–80 mL/min: 20 mg once daily; avoid in severe renal impairment (CrCl &lt;30 mL/min or hemodialysis)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: $T_{\text{max}}$, time to maximal effect; CYP, cytochrome P450; CrCl, creatinine clearance.
of significant hypotension, and, because of the long \( t_{1/2} \) of tadalafil, nitrates should not be administered for 48 hours following tadalafil administration.\(^{21} \) Caution is warranted when tadalafil is used in combination with certain antihypertensives such as alpha-adrenergic blocking agents (eg, doxazosin).\(^{21} \) PDE-5 inhibitors, including tadalafil, are contraindicated with riociguat, a recently approved agent for the treatment of PAH.\(^{27} \) Riociguat is a sGC stimulator that results in increased production of cGMP and resultant arterial vasodilation (Figure 1). Because PDE-5 inhibitors decrease degradation of cGMP, there is a risk of profound hypotension if administered concomitantly with riociguat. Though not documented, it would be expected that coadministration of tadalafil with prostacyclin analogs would increase the risk of hypotension and should be used with caution.

As of 2015, a monthly supply of Adcirca 40 mg once daily is estimated to cost about US$2,700. While there is currently no economic evidence comparing tadalafil to other PAH treatment options, several analyses have demonstrated a favorable cost-effective profile for sildenafil when compared to other PAH treatment options.\(^{28,29} \) Tadalafil may also be a cost-effective option; however, further research is needed to provide insight into tadalafil’s comparative cost-effectiveness. PAH treatment guidelines recommend using tadalafil in patients who are WHO functional class II or III.\(^{3,4,7,9} \) In recent years, a number of studies have provided insight into the clinical efficacy and effectiveness of tadalafil in the treatment of PAH (Table 3).\(^{24,30–41} \)

**Clinical efficacy**

**Monotherapy**

The earliest available literature providing evidence for the clinical utility of tadalafil in treating PAH came from case studies, as well as small prospective studies. From 2004 to 2008, a number of case studies were published that detailed the successful use of tadalafil in a total of 17 patients. From these various case reports, it is evident that tadalafil showed potential in providing PAH patients with improved exercise capacity.\(^{42–46} \) In 2004, a small prospective study gave insight into tadalafil’s potential to alter cardiopulmonary hemodynamics by demonstrating that one dose of tadalafil affected cardiopulmonary hemodynamics in a manner similar to that of sildenafil.\(^{30} \)

In 2007, results from two small prospective studies from India were published.\(^{31,32} \) The first study examined the effects of adding tadalafil to the current regimens of 13 patients with PAH caused by congenital disease, chronic pulmonary thromboembolism, and primary pulmonary hypertension.\(^{31} \) Baseline treadmill exercise capacity following Bruce protocol as well as hemodynamics were compared to those measured after 4 weeks of daily tadalafil doses of 20 mg or 40 mg. Treadmill exercise time significantly increased from a mean of 350.54 seconds to 479.54 seconds \((P<0.01)\). Improvements in functional class were seen in eleven of 13 patients. Patients also experienced a favorable although nonsignificant reduction in key measures of cardiopulmonary hemodynamics, including mPAP and mean PVR. The second study released that year showed benefit in eight patients with PAH related to congenital left to right shunt lesions during a randomized, double-blind, placebo-controlled crossover study.\(^{32} \) Patients received treatment with tadalafil 20 mg daily or placebo daily for 4 weeks. After completion of the first treatment arm of the study, patients underwent a washout period of 2 weeks, and then received the other treatment option for another 4 weeks. Outcome measures included change in 6MWD, pulmonary artery systolic pressure, Borg dyspnea score, and WHO functional class from baseline to week 4. There was a significant increase in 6MWD of 136.38 m on tadalafil compared to an increase of 46.5 m on placebo \((P=0.001)\). Additionally, significant decreases in pulmonary artery systolic pressure and Borg dyspnea scores were seen in patients while taking tadalafil.

In 2009, results from Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST)-1 Phase III clinical trial were published.\(^{33} \) The PHIRST-1 was a randomized, double-blind, multicenter, placebo-controlled, dose-ranging trial in 405 PAH patients with disease that was idiopathic or heritable in nature or related to anorexigen use, connective tissue disease, HIV infection, or congenital shunts. Patients were randomized to take placebo, tadalafil 2.5 mg, tadalafil 10 mg, tadalafil 20 mg, or tadalafil 40 mg once daily for 16 weeks. Patients who were receiving treatment with prostacyclin therapy were excluded; however, patients on stable treatment with bosentan could participate in the study. The primary endpoint was the change from baseline to week 16 in 6MWD. Secondary endpoints included changes in WHO functional class, time from randomization to clinical worsening, Borg dyspnea score, QoL, cardiopulmonary hemodynamics, and safety. The 6MWD, Borg dyspnea score, and WHO functional class were measured every 4 weeks during the study. Tadalafil doses of 10 mg, 20 mg, and 40 mg significantly improved the mean placebo-corrected 6MWD by 20 m \((P=0.047)\), 27 m \((P=0.028)\), and 33 m \((P<0.001)\), respectively, at week 16. No significant changes were seen in WHO functional class or Borg dyspnea scores. Time to clinical worsening
was significantly increased ($P=0.041$), and incidence of clinical worsening significantly decreased ($P=0.038$) only in the tadalafil 40 mg group when compared to placebo. Significant improvements in QoL as measured using validated questionnaires were also seen in patients taking tadalafil 40 mg. Cardiopulmonary hemodynamics, including mPAP and PVR, were significantly decreased in the tadalafil 0 mg group when compared to placebo. Significant improvements in WHO-FC, mPAP, PVR, and PVR/SVR were seen in patients taking tadalafil.

### Table 3: Chronological summary of studies demonstrating tadalafil clinical efficacy

<table>
<thead>
<tr>
<th>Tadalafil use</th>
<th>Author (year)</th>
<th>n*</th>
<th>Study design</th>
<th>WHO-FC</th>
<th>Outcome</th>
<th>Significant tadalafil findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monotherapy</td>
<td>Ghofrani et al (2004)</td>
<td>25</td>
<td>R, prospective study</td>
<td>II–IV</td>
<td>Change in PVRI from baseline to one dose</td>
<td>↓ PVRI</td>
</tr>
<tr>
<td></td>
<td>Aggarwal et al (2007)</td>
<td>13</td>
<td>Prospective, open-label study</td>
<td>II–IV</td>
<td>Treadmill exercise capacity and pulmonary hemodynamics from baseline to week four</td>
<td>↑ treadmill time, No change in mPAP and PVR</td>
</tr>
<tr>
<td></td>
<td>Bharani et al (2007)</td>
<td>8</td>
<td>R, DB, PLC, crossover study</td>
<td>II–III</td>
<td>Exercise capacity from baseline to week four</td>
<td>Improved functional class</td>
</tr>
<tr>
<td></td>
<td>Galí et al (2009), PHIRST-I study</td>
<td>405</td>
<td>R, DB, MC, PLC trial</td>
<td>I–IV</td>
<td>Exercise capacity from baseline to week 16</td>
<td>↑ 6MWD, ↓ PASP, ↓ Borg dyspnea score</td>
</tr>
<tr>
<td></td>
<td>Takatsuki et al (2012)</td>
<td>33</td>
<td>Retrospective study</td>
<td>I–IV</td>
<td>Pulmonary hemodynamics after transition from sildenafil in pediatric patients</td>
<td>↑ 6MWD, ↓ mPAP, ↓ PVR, and ↑ CI</td>
</tr>
<tr>
<td></td>
<td>Oudiz et al (2012), PHIRST-2 study</td>
<td>357</td>
<td>DB, MC, uncontrolled extension study</td>
<td>I–IV</td>
<td>Exercise capacity from baseline and week 16 for an additional 52 weeks after completing the PHIRST-I study</td>
<td>↑ QoL</td>
</tr>
<tr>
<td></td>
<td>Sabri and Beheshitan (2013)</td>
<td>18</td>
<td>Prospective, uncontrolled study</td>
<td>I–III</td>
<td>Clinical stability after transition from sildenafil</td>
<td>No improvements in Borg dyspnea score and WHO-FC</td>
</tr>
<tr>
<td></td>
<td>Shapiro et al (2013)</td>
<td>98</td>
<td>Retrospective study</td>
<td>NR</td>
<td>Clinical stability after transition from sildenafil</td>
<td>↓ mPAP, PVR and PVR/SVR</td>
</tr>
<tr>
<td></td>
<td>Frantz et al (2014)</td>
<td>35</td>
<td>MC, prospective, uncontrolled study</td>
<td>I–III</td>
<td>Treatment satisfaction after transition from sildenafil</td>
<td>No change in CI and 6MWD</td>
</tr>
<tr>
<td></td>
<td>Lichtblau et al (2015)</td>
<td>13</td>
<td>Retrospective study</td>
<td>II–IV</td>
<td>Clinical feasibility of transition from sildenafil after experiencing intolerable side effects</td>
<td>31/33 successfully transitioned</td>
</tr>
<tr>
<td>Combination therapy</td>
<td>Caojin et al (2014)</td>
<td>47</td>
<td>Prospective, open-label study</td>
<td>I–IV</td>
<td>Clinical benefit from baseline to 6 months after addition of tadalafil to inhaled iloprost</td>
<td>↑ 6MWD, ↓ PVR and ↑ systemic oxygen saturation</td>
</tr>
<tr>
<td></td>
<td>Zhuang et al (2014)</td>
<td>124</td>
<td>R, DB, PLC study</td>
<td>II–IV</td>
<td>Exercise capacity from baseline to week 16 after addition of tadalafil to stable ambrisentan therapy</td>
<td>↓ Borg dyspnea score, Improved WHO-FC</td>
</tr>
</tbody>
</table>

Notes: *Reported are sample sizes used during the analysis that generated tadalafil key findings. ↑, increased; ↓, decreased.

Abbreviations: PVRI, pulmonary vascular resistance index; mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; R, randomized; DB, double-blind; PLC, placebo-controlled; 6MWD, 6-minute walk distance; PASP, pulmonary artery systolic pressure; MC, multicenter; CI, cardiac index; QoL, quality of life; WHO-FC, World Health Organization functional class; SVR, systemic vascular resistance; NR, not reported; PHIRST, Pulmonary Arterial Hypertension and Response to Tadalafil; BNP, brain natriuretic peptide; TSQM, treatment satisfaction questionnaire for medication; CO, cardiac output.
The patients who had completed PHIRST-1 and the patients who had discontinued PHIRST-1 while taking placebo were eligible for continued participation in a double-blind, 52-week, uncontrolled extension study known as the PHIRST-2 study.65 Durability of efficacy and long-term safety were evaluated in the 357 patients who participated. If the patients were stable on tadalafil 20 mg from the PHIRST-1 study, they continued this treatment for 52 weeks. All the other patients received tadalafil 40 mg daily for 52 weeks. Durability of efficacy was assessed by comparing 6MWD across the PHIRST-1 and PHIRST-2 studies. WHO functional class and factors associated with clinical worsening were also assessed in patients who had received treatment with tadalafil 20 mg or tadalafil 40 mg in PHIRST-1. Improvements in 6MWD that were observed at the end of the PHIRST-1 study were maintained at week 52. In patients who had completed the PHIRST-1 study with placebo, tadalafil 2.5 mg, or tadalafil 10 mg, 6MWD improved at the end of week 52; however, the 6MWD did not improve to a level similar to that seen at the conclusion of PHIRST-1 in patients taking tadalafil doses of 20 mg or 40 mg. Multivariate analysis identified race, PAH etiology, duration of bosentan use, age, baseline WHO functional class, and 6MWD at PHIRST-1 baseline as the risk factors for clinical worsening.

In 2014, two post hoc analyses of the PHIRST studies were published.49,50 The first analysis looked at safety and efficacy differences in patients <65 (n=177) vs ≥65 (n=66) years of age at the time of PHIRST-1 study entry and who received placebo, tadalafil 20 mg, or tadalafil 40 mg.48 At the completion of the 16-week PHIRST-1 study, patients <65 years old had significantly increased 6MWD, while patients ≥65 years old had a nonsignificant increase in 6MWD. By the end of the 52-week PHIRST-2 study, 6MWD was significantly increased in both the age groups. There was also an observed trend of decreased incidence of clinical worsening; however, at no point did this trend become significant in either age group alone. The second analysis examined factors for association in achieving a clinically relevant response during the PHIRST-1 study.49 A clinically relevant response was defined as obtaining a minimal important difference (MID) in either 6MWD (MID = an increase >33 m) or in questionnaire scores measuring QoL (MID = a >5-unit increase in summary score). Using an adjusted logistic regression model, the patient factors of younger age, male sex, and lower baseline 6MWD were identified as being associated with a greater likelihood of achieving a clinically relevant response. A PAH etiology of connective tissue disorder was associated with a lower likelihood of achieving a clinically relevant response.

In recent years, several uncontrolled prospective and retrospective studies evaluating the use of tadalafil after transitioning from sildenafil have been published.24,34,35,37–39 These studies reported data from patients taking a final dose of sildenafil in the evening, and then starting tadalafil the next day. A successful transition from sildenafil to tadalafil was obtained in a combined total of 207 out of 232 patients. Generally, these studies showed that there was no change in 6MWD after transitioning. One study prospectively evaluated patient satisfaction after transitioning as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM). Scores relating to convenience after transitioning were increased; however, global TSQM scores did not change.24 Other studies demonstrated the clinical feasibility of transitioning to tadalafil in unique samples involving pediatric patients as well as in patients who had previously experienced intolerable side effects while taking sildenafil.34,39

In summary, the majority of evidence supporting the efficacy of tadalafil in PAH treatment comes from a large randomized clinical trial, the associated 52-week extension study which followed as well as from post hoc analyses of that clinical trial. In total, these studies provide strong evidence that tadalafil 40 mg significantly improves 6MWD for a sustained period of time. Additionally, tadalafil 40 mg improves cardiopulmonary hemodynamics, time to clinical worsening, and QoL.33,36,49,49 Several uncontrolled studies have provided some evidence supporting the effectiveness of switching from sildenafil to tadalafil.24,34,35,37–39

**Combination therapy**

Evidence for the use of tadalafil in combination with other PAH treatments was initially furnished by pharmacokinetic studies as well as case reports. In 2008, Wrishko et al showed that coadministration of tadalafil with bosentan, a P450 inducer, for 10 days in 14 healthy subjects decreased tadalafil exposure as measured by area under the curve (AUC) by 41.5% as well as decreased the maximum plasma concentration (C\textsubscript{max}) by 26.6%.25 Conversely, coadministration of tadalafil with ambrisentan in 23 healthy subjects did not result in decreased tadalafil plasma concentrations, including AUC or C\textsubscript{max}.50 Tadalafil pharmacokinetics were prospectively evaluated in 23 pediatric patients, 16 of whom were also taking bosentan. Along with age and estimated glomerular filtration rate, concomitant bosentan use was not found to have an effect on oral clearance (CL/F).51 From 2008 to 2011, four case studies detailed the successful and effective use of tadalafil in combination with a prostacyclin (n=4), sitaxentan (n=6), or a combination of bosentan and beraprost (n=1).52–55
A post hoc analysis of the PHIRST-1 study determined the effect of bosentan background therapy. Treatment-naïve patients who received placebo (n=37), tadalafil 20 mg (n=37), and tadalafil 40 mg (n=37) as well as patients with background bosentan exposure who received placebo (n=45), tadalafil 20 mg (n=45), and tadalafil 40 mg (n=42) were evaluated from baseline to week 16 for placebo-adjusted change in 6MWD, changes in functional class, incidence of clinical worsening, and cardiopulmonary hemodynamics. Only treatment-naïve patients receiving tadalafil 40 mg experienced a significant increase in placebo-adjusted 6MWD that failed to reach statistical significance. Background bosentan patients taking placebo experienced an increase in 6MWD of 19 m, while treatment-naïve patients taking placebo experienced a decrease in 6MWD of 3 m. The authors suggested that failure to show statistical significance in placebo-adjusted 6MWD in the background bosentan subgroup receiving tadalafil might be due, in part, to the increased 6MWD in background bosentan patients receiving placebo as well as the small sample sizes employed in the analyses. Another possible explanation for the decreased benefit in the background bosentan patients is reduced tadalafil serum concentrations as a result of CYP3A4 induction by bosentan. The incidence of clinical worsening was significantly lower in treatment-naïve patients receiving tadalafil 40 mg compared to that found in treatment-naïve patients receiving placebo. Changes in functional class and cardiopulmonary hemodynamics for all the subgroups also improved numerically but failed to reach statistical significance.

In 2014, results were published from two prospective studies from the People’s Republic of China examining the efficacy of tadalafil when used in various combinations with other PAH treatments. The first study was a prospective, uncontrolled, open-label evaluation of 47 patients with PAH secondary to congenital heart disease. Patients received a low dose of iloprost administered as 2.5 µg inhaled six times a day for 6 months and then were started on tadalafil 5 mg once daily in combination with iloprost for an additional 6 months. Outcome measures included change in 6MWD, Borg dyspnea score, oxygen saturation, WHO functional class, and cardiopulmonary from baseline to 6 months of monotherapy with iloprost. These same measures were assessed again after an additional 6 months in order to compare results of iloprost monotherapy with combination therapy. Iloprost monotherapy resulted in significant improvements in 6MWD, Borg dyspnea score, oxygen saturation, and WHO functional class. Following 6 months of combination therapy, there were additional significant improvements in these same measures when compared to values obtained at the end of 6 months of monotherapy. The 6MWD significantly increased from a mean of 457.22 m after monotherapy to a mean of 490.09 m (P<0.05) after combination therapy. Additionally, WHO functional class, Borg dyspnea scores, and measures of cardiopulmonary hemodynamics, including PVR, decreased significantly, while systemic oxygen saturation during exercise increased significantly.

The second study conducted exclusively in the People’s Republic of China was a randomized, double-blind, placebo-controlled study evaluating the benefits of adding tadalafil in 124 stable patients who had previously received ambrisentan 10 mg daily for 4 months. The study included patients with idiopathic or heritable PAH or with PAH related to anorexigen use, connective tissue disease, or repaired congenital heart disease. Patients were randomized to either placebo or tadalafil 40 mg daily for 16 weeks in addition to ambrisentan. Outcome measures included change in 6MWD, WHO functional class, incidence of clinical worsening, and cardiopulmonary hemodynamics assessed every 4 weeks from baseline to week 16. The 6MWD was found to be significantly increased from baseline at weeks 8, 12, and 16 in patients receiving tadalafil combination, whereas the 6MWD was not found to be significantly increased from baseline at any week in patients receiving placebo. When compared between groups at week 16, 6MWD was found to be significantly greater by 36.1 m (P=0.042) in patients receiving tadalafil combination compared to patients receiving placebo combination. By week 16, there were nine fewer incidences of clinical worsening in the tadalafil treatment group (P=0.046); however, there were no significant improvements in WHO functional class or cardiopulmonary hemodynamics.

In summary, subgroup analysis of the PHIRST-1 study indicates that there may be some additional benefit in using tadalafil in combination with bosentan; however, results from this analysis failed to be statistically significant and conclusions were based on small sample sizes. Some evidence is available supporting tadalafil use in combination with iloprost. Finally, as demonstrated by one randomized study, tadalafil may provide additional benefit when used in combination with ambrisentan in increasing 6MWD and decreasing incidence of clinical worsening. As opposed to bosentan, ambrisentan does not induce CYP3A and would not be expected to decrease tadalafil serum concentrations nor therapeutic efficacy. Strong evidence for tadalafil use in combination therapy is lacking.
and larger controlled studies will need to be performed in order to better understand what role, if any, tadalafil has when used in combination with PAH therapies.

**Safety and tolerability**

Tadalafil is considered to be safe and typically well tolerated when taken for the treatment of PAH. The most common adverse event (AE) associated with tadalafil use is headache. Approximately 15%, 32%, and 42% of patients during the PHIRST-1 study experienced headache while taking placebo, tadalafil 20 mg, and tadalafil 40 mg, respectively. These values dropped to 14% and 16% during the 52-week PHIRST-2 extension study for tadalafil 20 mg and tadalafil 40 mg, respectively. Other AEs, including myalgias and flushing, were reported at a lesser frequency than headache and were typically mild-to-moderate in intensity. Discontinuation rates during the PHIRST-1 study were ~16% and were similar in all treatment groups. Discontinuation rates after 52 weeks of therapy remained similar to those seen during the PHIRST-1 study.5, 36 Furthermore, discontinuation rates in elderly patients did not appear to differ from those observed in younger patients.48 When tadalafil was used as an alternative after transitioning from sildenafil, tolerability of tadalafil was reported in the majority of patients.24, 34, 35, 37–39 Additionally, one study reported that about half of the patients who had experienced intolerable AEs while taking sildenafil were able to tolerate and successfully transition to tadalafil.39 Although data are limited, incidence of AEs appears to be similar in pediatric population.34

Studies evaluating tadalafil safety when used in combination with other PAH treatment options did not report a significantly increased incidence of AEs for tadalafil combination use with bosentan, ambrisentan, and inhaled iloprost. Discontinuation rates also remained similar to those rates observed in patients on tadalafil monotherapy.40, 41, 56 In addition to mild-to-moderate AEs, rare but serious AEs associated with tadalafil may occur, including vision loss, hearing loss, and priapism.21

**Conclusion**

Tadalafil is a convenient and generally well tolerated once-a-day PDE-5 inhibitor for treating patients with PAH. There is strong evidence that tadalafil at doses of 40 mg daily improves exercise capacity for sustained periods of time when used as monotherapy with WHO group I PAH patients with WHO functional class II or III symptoms. Tadalafil may also be beneficial at improving cardiopulmonary hemodynamics, QoL, and time to clinical worsening. Data from uncontrolled studies indicate that tadalafil may be a suitable alternative to sildenafil for patients desiring decreased pill burden. While the role for tadalafil in combination therapy appears promising, evidence-based recommendations for tadalafil use in combination therapy are currently difficult given the lack of evidence from large controlled trials.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


